An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants

被引:40
作者
Ku, YM [1 ]
Min, DI [1 ]
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
关键词
tacrolimus; AUC monitoring; liver transplant;
D O I
10.1097/00007691-199804000-00014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This study aims to assess the predictability of individual tacrolimus (FK) concentrations at different time points for the area under the curve (AUG) and to find the best sampling time for the abbreviated AUC to predict the total body exposure of FK. A total of 23 FK blood concentration versus time profiles (11 blood samples per 12 hours) was studied in 12 stable patients with liver transplants at steady state. Each AUC was calculated by the trapezoidal rule, and the relationship between individual concentrations or abbreviated AUC and total AUC was determined by linear regression. The trough concentrations from the morning dose predict AUC better than the trough concentration from the evening dose (r(2) = 0.71 for morning dose and r(2) = 0.35 for evening dose). In the case of single drug concentration, the 4-hour concentration could predict the total AUC reasonably well (r(2) = 0.73). From stepwise multiple regression, the abbreviated AUC at 1, 2.5, 6, and 9 hours could predict the total AUC most accurately (r(2) = 0.99). This study shows that the four levels at 1, 2.5, 6, and 9 hours or 1, 4, and 12 hours as an abbreviated AUC is as good as a full pharmacokinetic study. Alternatively, 4-hour concentration is a good predictor of the total body exposure of FK in the stable patients with liver transplants.
引用
收藏
页码:219 / 223
页数:5
相关论文
共 20 条
[1]  
*ABB LAB DIAGN DIV, 1993, TRANSPL DIAGN TACR A
[2]  
BACKMAN L, 1994, TRANSPLANT P, V26, P1804
[3]  
BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110
[4]  
ERDEN E, 1994, TRANSPLANTATION, V58, P397
[5]  
GREVEL J, 1991, CLIN CHEM, V37, P1905
[6]   TACROLIMUS, A NEW IMMUNOSUPPRESSANT - A REVIEW OF THE LITERATURE [J].
HOOKS, MA .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (04) :501-511
[7]   PHARMACOKINETICS OF TACROLIMUS IN LIVER-TRANSPLANT PATIENTS [J].
JUSKO, WJ ;
PIEKOSZEWSKI, W ;
KLINTMALM, GB ;
SHAEFER, MS ;
HEBERT, MF ;
PIERGIES, AA ;
LEE, CC ;
SCHECHTER, P ;
MEKKI, QA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :281-290
[8]   CONSENSUS DOCUMENT - THERAPEUTIC MONITORING OF TACROLIMUS (FK-506) [J].
JUSKO, WJ ;
THOMSON, AW ;
FUNG, J ;
MCMASTER, P ;
WONG, SH ;
ZYLBERKATZ, E ;
CHRISTIANS, U ;
WINKLER, M ;
FITZSIMONS, WE ;
LIEBERMAN, R ;
MCBRIDE, J ;
KOBAYASHI, M ;
WARTY, V ;
SOLDIN, SJ .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :606-614
[9]   THE ABILITY OF PRETRANSPLANT TEST-DOSE PHARMACOKINETIC PROFILES TO REDUCE EARLY ADVERSE EVENTS AFTER RENAL-TRANSPLANTATION [J].
KAHAN, BD ;
WELSH, M ;
RUTZKY, L ;
LEWIS, R ;
KNIGHT, R ;
KATZ, S ;
NAPOLI, K ;
GREVEL, J ;
VANBUREN, CT .
TRANSPLANTATION, 1992, 53 (02) :345-351
[10]   CHALLENGES IN CYCLOSPORINE THERAPY - THE ROLE OF THERAPEUTIC MONITORING BY AREA-UNDER-THE-CURVE MONITORING [J].
KAHAN, BD ;
WELSH, M ;
RUTZKY, LP .
THERAPEUTIC DRUG MONITORING, 1995, 17 (06) :621-624